000 01368 a2200313 4500
005 20250515083059.0
264 0 _c20080310
008 200803s 0 0 eng d
022 _a0931-0509
024 7 _a10.1093/ndt/gfm434
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aRay, Joshua A
245 0 0 _aCost-utility analysis of cinacalcet in addition to standard of care in the UK.
_h[electronic resource]
260 _bNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
_cNov 2007
300 _a3355-7; author reply 3357-8 p.
_bdigital
500 _aPublication Type: Letter; Comment
650 0 4 _aCinacalcet
650 0 4 _aCost-Benefit Analysis
650 0 4 _aHumans
650 0 4 _aHyperparathyroidism, Secondary
_xdrug therapy
650 0 4 _aKidney Failure, Chronic
_xcomplications
650 0 4 _aNaphthalenes
_xeconomics
650 0 4 _aParathyroid Hormone
_xblood
650 0 4 _aUnited Kingdom
700 1 _aValentine, William J
700 1 _aPalmer, Andrew J
773 0 _tNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
_gvol. 22
_gno. 11
_gp. 3355-7; author reply 3357-8
856 4 0 _uhttps://doi.org/10.1093/ndt/gfm434
_zAvailable from publisher's website
999 _c17314243
_d17314243